AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio...
In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and...
11.08.2017
- Ireland-domiciled drugmaker Shire is considering splitting off its neuroscience division into a separate, publicly listed company. The move, revealed during its second-quarter...
31.05.2017
- US drugmaker Merck has bought an exclusive global licence from Japan’s Teijin Pharma to develop, manufacture and commercialize an investigational preclinical antibody candidate...
27.04.2017
- Bioelectronic technologies for modulating the signaling capabilities of the nervous system could pose challenges for producers of medicinal materials and chemicals – but also for...
01.08.2016
- Long-time Eli Lilly chairman and CEO, John C. Lechleiter, has announced plans to retire in December of this year after 30 years with the US drugmaker. Succeeding the 62-year-old...
19.05.2016
- Swiss drugmaker Novartis has announced plans to split its Pharmaceutical division into two business units, Novartis Pharmaceutical and Novartis Oncology. The first-mentioned will...
24.08.2015
- Novartis is acquiring all the remaining rights to GlaxoSmithKline’s (GSK) multiple sclerosis (MS) drug, Ofatumumab. A fully human monoclonal antibody which targets the CD20...
